NSI-189 NSI-189 is a nootropic and neurogenic research chemical derive
Place of Origin:
Anesthetic Agents, Antibiotic and Antimicrobial Agents, Antineoplastic Agents, Antiparasitic Agents, Antipyretic Analgesics and NSAIDs, Central Nervous System Agents, Immune Function Agents, Vitamins, Amino Acids and Coenzymes
NSA-189 is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus, an area of the brain believed to be contributory in MDD and other conditions, such as Alzheimer’s disease and Post-traumatic stress disorder (PTSD). Phase 1b of the clinical trial is to test the safety and tolerability of the drug in depressed patients.
NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation.
NSI-189 has been shown to increase the hippocampal volume of healthy adult mice by 20%.
Clinical trials NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers, with no adverse effects reported.
A phase 1B clinical trial for treating major depressive disorder in 24 patients started in 2012, with study completion expected in January 2014.
Assuming positive outcomes in the phase 1b clinical trial, Neuralstem intends to pursue further clinical trials for a variety of encephalopathic conditions including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke and natural aging.